Furthermore, those on insulin in the WG medication group are likely to have had T2D for a longer duration, indicating a more advanced stage of diabetes that could exacerbate corneal nerve damage directly or through comorbidities such as obesity, abnormal lipid profiles, and renal impairment. The gene discussed is INS; the disease is Obesity.